Lentiviralâvectorâbased therapies, widely used for treating various diseases, face limitations because of release burst, rapid clearance, and immune activation. Herein, a lentiviral vector delivery platform is proposed utilizing a virusâengineered microsol electrospun scaffold. Identifying a remarkable upregulation of polypyrimidine tract binding protein1 (PTB) in spinal cord injury (SCI) rats, a scaffold  is constructed comprising a hyaluronic acid (HA) core encapsulating brainâderived neurotrophic factor (BDNF) and a polydopamine (PDA)âmodified linear polyâlâlactic acid (PLLA) shell, with shPTB lentiviral vectors (LVâshPTB) grafted via PDA. In vitro, the LVâshPTB achieves an infection efficiency of 70%, and the oriented scaffolds significantly reduce the expression of inflammatory factors, induce the reprogramming of fibroblasts into neurons, and sustain the release of BDNF for over 2 weeks. In vivo, the scaffolds provide physical support and neural guidance, as well as released BDNF and LVâshPTB. LVâshPTB delivery leads to the reprogramming of fibroblasts into neurons, and the sustained BDNF delivery maintains the neuronsâ proliferation and growth, which further promotes the recovery of neurological function in SCI rats. These results demonstrate the potential application of virusâengineered delivery platforms in SCI treatment and other medical fields.